SLN
Silence Therapeutics plc NASDAQ Listed Sep 8, 2020$7.53
After hrs
$7.40
-1.73%
Mkt Cap $355.7M
52w Low $4.19
79.3% of range
52w High $8.40
50d MA $6.83
200d MA $6.09
P/E (TTM)
—
EV/EBITDA
—
P/B
5.7x
Debt/Equity
0.0x
ROE
-142.2%
P/FCF
-5.3x
RSI (14)
50.40
ATR (14)
$0.54
Beta
1.33
50d MA
$6.83
200d MA
$6.09
Avg Volume
229.3K
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
72 Hammersmith Road · London W14 8TH · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 7.36 | -1.2% | -5.6% | +0.3% | +2.9% | -5.3% | +2.8% | — |
| Mar 5, 2026 | AMC | -0.32 | -0.25 | +21.9% | 5.50 | -1.1% | +13.3% | -0.6% | +1.3% | +11.3% | -0.1% | — |
| Nov 6, 2025 | AMC | -0.40 | -0.45 | -12.5% | 6.45 | -1.1% | +2.0% | -3.5% | +5.8% | +0.1% | +2.8% | — |
| Aug 7, 2025 | AMC | -0.27 | -0.54 | -100.0% | 5.38 | -2.4% | -6.3% | +1.0% | +9.8% | +4.7% | -3.8% | — |
| May 8, 2025 | AMC | -0.18 | -0.60 | -233.3% | 3.56 | +0.6% | +3.9% | +3.5% | +7.3% | -1.2% | -1.2% | — |
| Feb 27, 2025 | AMC | -0.45 | 0.27 | +160.0% | 4.72 | -0.4% | -4.7% | -4.0% | +3.7% | +5.6% | +0.2% | — |
| Nov 14, 2024 | AMC | -0.42 | -0.75 | -78.6% | 13.98 | +0.1% | -9.2% | -13.2% | -36.8% | -0.6% | +10.8% | — |
| May 16, 2024 | AMC | -0.23 | -0.05 | +78.3% | 22.94 | +1.0% | +0.3% | +1.5% | +2.4% | -2.9% | -5.3% | — |
| Nov 14, 2023 | AMC | -0.56 | -0.28 | +50.0% | 9.22 | +2.6% | +2.2% | -1.3% | -2.2% | +8.9% | +8.6% | — |
| Aug 16, 2023 | AMC | -0.59 | -0.36 | +39.0% | 6.50 | +0.0% | +4.8% | +2.6% | +0.0% | +6.9% | +13.7% | — |
| May 16, 2023 | AMC | -0.51 | -0.35 | +31.4% | 5.96 | -0.2% | -8.6% | +10.6% | -0.8% | +0.3% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.97 | $7.00 | +0.4% | -1.0% | +6.5% | -6.0% | -4.1% | -3.8% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.73 | $4.74 | +0.2% | +2.5% | +3.3% | +0.4% | -2.8% | +3.1% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $5.38 | $5.25 | -2.4% | -6.3% | +1.0% | +9.8% | +4.7% | -3.8% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.59 | $5.50 | -1.6% | -4.7% | -5.1% | +6.1% | +5.4% | +5.1% |
| Jun 13 | Chardan Capital | Maintains | Buy → Buy | — | $5.59 | $5.50 | -1.6% | -4.7% | -5.1% | +6.1% | +5.4% | +5.1% |
| May 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $3.56 | $3.58 | +0.6% | +3.9% | +3.5% | +7.3% | -1.2% | -1.2% |
| May 9 | Goldman Sachs | Maintains | Sell → Sell | — | $3.56 | $3.58 | +0.6% | +3.9% | +3.5% | +7.3% | -1.2% | -1.2% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.56 | $3.58 | +0.6% | +3.9% | +3.5% | +7.3% | -1.2% | -1.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.74 | $4.75 | +0.2% | +2.3% | -7.2% | -6.2% | +0.7% | -4.5% |
| Mar 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.48 | $4.46 | -0.4% | +5.6% | +0.2% | +2.3% | -7.2% | -6.2% |
| Mar 4 | BMO Capital | Maintains | Outperform → Outperform | — | $4.32 | $4.18 | -3.2% | +3.7% | +5.6% | +0.2% | +2.3% | -7.2% |
| Mar 4 | Goldman Sachs | Maintains | Sell → Sell | — | $4.32 | $4.18 | -3.2% | +3.7% | +5.6% | +0.2% | +2.3% | -7.2% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.33 | $5.13 | -3.8% | -5.1% | +10.9% | +7.8% | -5.0% | -12.9% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.34 | $5.35 | +0.2% | -1.9% | +0.2% | +1.5% | -5.1% | +10.9% |
| Dec 10 | Chardan Capital | Maintains | Buy → Buy | — | $7.99 | $8.02 | +0.4% | -7.4% | -12.8% | +2.3% | -2.3% | +4.5% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.45 | -0.8% | -6.2% | -7.4% | -12.8% | +2.3% | -2.3% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.97 | $7.10 | +1.9% | -0.6% | +10.8% | -8.7% | +2.9% | +3.5% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.98 | $14.00 | +0.1% | -9.2% | -13.2% | -36.8% | -0.6% | +10.8% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $15.24 | $15.20 | -0.3% | -8.3% | -9.2% | -13.2% | -36.8% | -0.6% |
| Oct 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $18.61 | $18.60 | -0.1% | +4.5% | -0.8% | -0.5% | +2.3% | -4.4% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.75 | $18.66 | -0.5% | +1.8% | +0.4% | +0.4% | -2.1% | -1.1% |
| Aug 16 | Chardan Capital | Maintains | Buy → Buy | — | $16.77 | $16.37 | -2.4% | -6.4% | +1.3% | +0.0% | -0.4% | -2.0% |
| Jun 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.00 | $20.00 | +5.3% | +0.0% | -1.4% | -3.6% | -0.5% | +1.3% |
| Jun 28 | Chardan Capital | Maintains | Buy → Buy | — | $19.00 | $20.00 | +5.3% | +0.0% | -1.4% | -3.6% | -0.5% | +1.3% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.31 | $18.36 | +0.3% | +3.8% | +0.0% | -1.4% | -3.6% | -0.5% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.90 | $19.50 | +3.2% | +0.0% | +4.0% | +3.6% | -2.0% | -8.2% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $21.81 | +0.0% | -3.8% | -1.7% | -3.8% | +0.8% | +1.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.00 | $22.45 | +2.0% | -0.4% | +0.8% | -2.5% | +1.3% | -3.8% |
| May 17 | Chardan Capital | Maintains | Buy → Buy | — | $22.94 | $23.17 | +1.0% | +0.3% | +1.5% | +2.4% | -2.9% | -5.3% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.94 | $23.17 | +1.0% | +0.3% | +1.5% | +2.4% | -2.9% | -5.3% |
| Apr 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $22.64 | $22.64 | +0.0% | -0.6% | +0.0% | -1.1% | -2.9% | -0.0% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.83 | $23.97 | +0.6% | -4.2% | +5.1% | -2.8% | -1.8% | -1.0% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $25.61 | $27.27 | +6.5% | -7.0% | -4.2% | +5.1% | -2.8% | -1.8% |
| Mar 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.61 | $27.27 | +6.5% | -7.0% | -4.2% | +5.1% | -2.8% | -1.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.90 | $24.60 | -5.0% | -1.1% | -7.0% | -4.2% | +5.1% | -2.8% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.80 | $24.04 | +1.0% | -3.1% | +1.7% | +2.3% | +6.4% | +0.6% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.08 | $18.41 | +1.8% | +5.3% | -3.3% | +2.6% | -0.5% | +1.7% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.30 | $9.11 | -2.0% | -2.2% | +8.9% | +8.6% | +7.3% | +1.8% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.50 | $6.50 | +0.0% | +4.8% | +2.6% | +0.0% | +6.9% | +13.7% |
| Aug 17 | Chardan Capital | Maintains | Buy → Buy | — | $6.50 | $6.50 | +0.0% | +4.8% | +2.6% | +0.0% | +6.9% | +13.7% |
| Jul 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.56 | $5.74 | +3.2% | -4.9% | -4.2% | +5.7% | +0.4% | +2.2% |
| Jul 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.80 | $5.99 | +3.3% | +1.2% | -1.2% | -11.4% | +3.9% | +4.1% |
| Jun 26 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.65 | $6.71 | +0.9% | -2.3% | -0.0% | -2.1% | -8.6% | -5.3% |
| May 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.45 | $5.60 | +2.8% | +10.6% | -0.8% | +0.3% | +0.7% | -4.0% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.17 | $6.08 | -1.4% | -0.2% | -6.4% | +1.9% | +1.5% | -8.6% |
| May 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.35 | $6.82 | +7.4% | +1.6% | +1.4% | -5.7% | -0.2% | -6.4% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.99 | $8.91 | -0.9% | -3.2% | +3.7% | -0.7% | -0.9% | +1.4% |
| Mar 16 | Chardan Capital | Maintains | Buy → Buy | — | $9.16 | $9.60 | +4.8% | -1.9% | -3.2% | +3.7% | -0.7% | -0.9% |
| Dec 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.23 | $15.59 | +2.4% | +1.9% | -1.4% | -4.6% | +2.2% | -4.5% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.09 | $17.14 | +0.3% | -5.5% | -3.7% | -2.1% | +1.9% | -1.4% |
No insider trades available.
8-K · 8.01
!! High
Silence Therapeutics plc -- 8-K 8.01: Material Event / Announcement
Jun 11
8-K · 2.02
!! High
Silence Therapeutics plc -- 8-K 2.02: Earnings Results
Silence Therapeutics reported Q1 2026 financial results and business updates, signaling operational progress that investors should monitor for revenue growth and pipeline advancement metrics.
May 7
8-K · 7.01
! Medium
Silence Therapeutics Plc American Depository Share -- 8-K 7.01: Regulation FD Disclosure
Silence Therapeutics updated its corporate presentation on March 5, 2026, with business updates now available on its investor relations website, providing shareholders with current company information.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 1,234,807 | $7M | Added | Mar 2026 |
| 2 | Millennium Management | 1,074,191 | $6M | Added | Mar 2026 |
| 3 | Morgan Stanley | 649,260 | $4M | Reduced | Dec 2025 |
| 4 | Jones Hill Capital Lp | 301,604 | $2M | New | Mar 2026 |
| 5 | Sg Americas Securities, Llc | 286,698 | $2M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 246,937 | $1M | Added | Mar 2026 |
| 7 | Bank Of Montreal /can/ | 202,901 | $1M | Added | Mar 2026 |
| 8 | Adar1 Capital Management, Llc | 172,157 | $907K | New | Mar 2026 |
| 9 | Marshall Wace, Llp | 169,616 | $894K | Added | Mar 2026 |
| 10 | Bnp Paribas Financial Markets | 147,668 | $778K | Added | Mar 2026 |
| 11 | Ishara Investments Lp | 140,500 | $740K | Reduced | Mar 2026 |
| 12 | Point72 Asset Management | 119,711 | $631K | Added | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 115,281 | $608K | Added | Mar 2026 |
| 14 | Qube Research & Technologies Ltd | 104,555 | $551K | Added | Mar 2026 |
| 15 | M28 Capital Management Lp | 101,203 | $533K | Reduced | Mar 2026 |
| 16 | Opaleye Management Inc. | 78,926 | $480K | New | Dec 2025 |
| 17 | Jane Street Group, Llc | 29,168 | $177K | New | Dec 2025 |
| 18 | Bank Of America Corp /de/ | 29,773 | $157K | Added | Mar 2026 |
| 19 | Raymond James Financial Inc | 25,000 | $132K | — | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 16,203 | $85K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 173,313 | $913K | Mar 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 29,538 | $161K | Feb 2026 |
| 3 | Invesco Nasdaq Biotechnology ETF | 2,621 | $14K | Feb 2026 |
| 4 | ProShares Ultra Nasdaq Biotechnology | 2,169 | $12K | Feb 2026 |
Valuation
Market Cap
$355.7M
Enterprise Value
$242.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.16x
P/B
5.71x
P/S
385.95x
P/FCF
-5.25x
EV/EBITDA
—
Shares Out
47.2M
Financials (TTM)
Revenue
$921K
Net Income
-$85.2M
EBITDA
-$78.1M
Free Cash Flow
-$62.3M
Op Cash Flow
-$46.3M
EPS Basic
$-1.89
EPS Diluted
$-4.32
EPS Forward
$-0.54
Gross Margin
66.4%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$131.4M
Total Liab.
$69.1M
Total Equity
$62.3M
Cash
$85.1M
LT Debt
-$71K
Book Value/Sh
$1.32
Debt/Equity
0.00x
Current Ratio
8.72
Quick Ratio
8.72
Returns & Growth
ROE
-142.2%
ROA
-67.4%
ROIC
-70.0%
Rev Growth YoY
-98.7%
EPS Growth YoY
+20.2%
Price Returns
2W
-3.2%
1M
-5.6%
3M
+26.8%
6M
+2.4%
12M
+18.2%
Technicals
52W High
$8.40
52W Low
$4.19
50d MA
$6.83
200d MA
$6.09
RSI (14)
50.40
ATR (14)
$0.54
Beta
1.33
Avg Volume
229K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$57.00
High
$67.00
Low
$49.00
Median
$55.00
Data updated apr 27, 2026 1:42am
· Source: financialmodelingprep.com